Newron Pharmaceuticals

Overview
Price performance
Financials
Research
Sector insights
Thematics

Newron Pharmaceuticals is focused on the central nervous system. Xadago for Parkinson’s disease (PD) is sold in Europe, Japan, the United States and other regions. Evenamide, a novel schizophrenia add-on therapy, is involved in a Phase II/III trial programme targeting schizophrenia.

Xadago is marketed as an add-on to levodopa therapy in PD. It is currently sold in Europe, Japan, the United States and other territories. Generic manufacturers have notified the FDA of their intention to file generic Xadago products. Newron is contesting these filings. Xadago is currently patent protected until at least 2027.

Latest Insights

Healthcare |
Update

20.03.24

Newron Pharmaceuticals — Evenamide set for a pivotal year

Healthcare |
Flash note

15.03.24

Newron Pharmaceuticals — Operational flexibility with new/updated financing

Healthcare |
Update

05.01.24

Newron Pharmaceuticals — TRS data green-lights evenamide Phase III plans

Healthcare |
Update

11.10.23

Newron Pharmaceuticals — Positive readout highlights evenamide potential

Visit Website

Sector

Healthcare

Equity Analyst

Soo Romanoff

Managing Director - Head of Content, Healthcare

Nidhi Singh

Analyst

Arron Aatkar

Associate analyst

Jyoti Prakash

Analyst, Healthcare

Key Management

Marco Caremi

Executive VP of Business Development
Stefan Weber

CEO

Balance Sheet

Forecast net cash (€m)

29.1

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
%	1M	3M	12M
Actual	(5.9)	(10.3)	43.4
Relative	(4.4)	(12.8)	43.3
52 week high/low	CHF10.4/CHF3.9

Financials

Newron is developing evenamide as an add-on therapy for poorly managed and treatment-resistant schizophrenia (TRS). A potentially pivotal Phase III trial (study 008A) in patients with schizophrenia who are taking antipsychotics but not classified as having TRS is ongoing; readouts are expected in March 2024. For the Phase II trial (study 014/015) in patients with TRS, encouraging final results (12-month data for the full patient cohort) were announced in January 2024, which showed that evenamide was both safe and efficacious. Over 70% of patients experienced a clinically meaningful reduction in disease severity and 25% achieved remission. Newron intends to begin an additional, potentially pivotal, multinational Phase III programme in TRS patients (expected to start in Q124). In its H123 results, Newron recorded total revenue of €5.5m for the period, nearly double H122’s revenue of €2.8m, primarily driven by higher royalty income for Xadago.